In The News
Top 10 class action settlements of 2024
High Court asked to weigh in on Katy Perry trade mark stoush
Toyota unit Hino to pay $87M to settle emissions cheating class action
Tougher penalties floated for improper legal privilege claims
Dominique Grubisa, Master Wealth lose challenge to $6M penalty
‘Considerable disquiet’: Pelvic mesh group members can challenge $405M settlements
Judge rejects sacked Super Retail Group execs’ settlement claims
$56M settlement approved in Monash IVF class action
Kids clothing retailer hit with $5M penalty for worker exploitation
Third person sentenced over $180M Courtenay House Ponzi scheme
Please login to bookmarkClose

Israeli drug company Neurim Pharmaceuticals has lost a bid to patent a mini version of its melatonin tablet Circadin for children, after a successful challenge by Australian drug maker Generic Partners.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au